Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at 5gstockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. 5GStockMovers.com also follow companies like; Verizon (VZ), SBA Communications Corp (SBAC), American Tower Corp. (AMT), AT&T Inc. (T), Nvidia Corp. (NVDA), Qualcomm Inc. (QCOM).
Recent TECH Stock Price: $374.43
Summary: Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Jacob Johnson analyst at Stephens reiterates coverage on Bio-Techne (TECH) stock in the energy sector with a Buy rating and has set TECH's stock price target at $ 480.
TipRanks.com reports that Bio-Techne currently has 7 analysts offering 12-month price targets on TECH and the consensus is a Strong Buy rating with an average stock price target of $494.43. The most recent TECH stock price we have is $374.43 and we are not making any TECH forecasts at this time.
In addition, TradingView issued a Neutral rating for TECH over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TECH. 5gstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TECH, please click here >>
Staar Surgical, STAA
Recent STAA Stock Price: $102.03
Summary: Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
William Plovanic analyst at Canaccord Genuity reiterates coverage on Staar Surgical (STAA) stock in the energy sector with a Buy rating and has set STAA's stock price target at $ 97.
TipRanks.com reports that Staar Surgical currently has 5 analysts offering 12-month price targets on STAA and the consensus is a Strong Buy rating with an average stock price target of $110.40. The most recent STAA stock price we have is $102.03 and we are not making any STAA forecasts at this time.
In addition, TradingView issued a Strong Buy rating for STAA over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on STAA. 5gstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on STAA, please click here >>
NeoGenomics, NEO
Recent NEO Stock Price: $12.29
Summary: NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
Mark Massaro analyst at BTIG reiterates coverage on NeoGenomics (NEO) stock in the energy sector with a Hold rating and has set NEO's stock price target at n/a.
TipRanks.com reports that NeoGenomics currently has 7 analysts offering 12-month price targets on NEO and the consensus is a Moderate Buy rating with an average stock price target of $16.00. The most recent NEO stock price we have is $12.29 and we are not making any NEO forecasts at this time.
In addition, TradingView issued a n/a rating for NEO over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on NEO. 5gstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NEO, please click here >>
Aldeyra Therapeutics, ALDX
Recent ALDX Stock Price: $6.99
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
Matthew Caufield analyst at H.C. Wainwright reiterates coverage on Aldeyra Therapeutics (ALDX) stock in the energy sector with a Buy rating and has set ALDX's stock price target at $ 15.
TipRanks.com reports that Aldeyra Therapeutics currently has n/a analysts offering 12-month price targets on ALDX and the consensus is a Strong Buy rating with an average stock price target of n/a. The most recent ALDX stock price we have is $6.99 and we are not making any ALDX forecasts at this time.
In addition, TradingView issued a Buy rating for ALDX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALDX. 5gstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALDX, please click here >>
The editors at 5gstockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
5GStockMovers.com (FGSM) is a no cost internet site and email newsletter built for investors who are interested in the top 5G stocks. Some investors prefer 5G stocks under $5, some prefer 5G stocks under $10, and others just want cheap 5G stocks. health insurance stocks, and health tech stocks. (FGSM) aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind (FGSM) consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by (FGSM) contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks. 5G stocks that might be included in one of our reports may include companies like; Verizon (VZ), SBA Communications Corp. (SBAC), American Tower Corp. (AMT), AT&T Inc. (T), Nvidia Corp. (NVDA), Qualcomm Inc. (QCOM)
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================